Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Front Cell Dev Biol ; 8: 256, 2020.
Article in English | MEDLINE | ID: mdl-32373611

ABSTRACT

Valosin-containing protein (VCP), also called p97, is an evolutionarily conserved and ubiquitously expressed ATPase with diverse cellular functions. Dominant mutations in VCP are found in a late-onset multisystem degenerative proteinopathy. The neurological manifestations of the disorder include frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). In these patients, long motor neuron axons could be particularly susceptible to defects in axonal transport. However, whether VCP has a physiological function in maintaining axonal transport and whether this role is impaired by disease-causing mutations remains elusive. Here, by employing live-imaging methods in Drosophila larval axons and performing genetic interaction experiments, we discover that VCP regulates the axonal transport of mitochondria. Downregulation of VCP enhances the retrograde transport of mitochondria and reduces the density of mitochondria in larval axons. This unidirectional motility phenotype is rescued by removing one copy of the retrograde motor dynein heavy chain (DHC), or elevating Miro which facilitates anterograde mitochondrial movement by interacting with the anterograde motor kinesin heavy chain (KHC). Importantly, Miro upregulation also significantly improves ATP production of VCP mutant larvae. We investigate human VCP pathogenic mutations in our fly system. We find that expressing these mutations affects mitochondrial transport in the same way as knocking down VCP. Our results reveal a new role of VCP in mediating axonal mitochondrial transport, and provide evidence implicating impaired mitochondrial motility in the pathophysiology of VCP-relevant neurodegenerative diseases.

2.
Behav Brain Res ; 326: 226-236, 2017 05 30.
Article in English | MEDLINE | ID: mdl-28284952

ABSTRACT

The behavioral manifestations of psychostimulant-induced sensitization vary markedly between young and adult rats, suggesting that the neural mechanisms mediating this phenomenon differ across ontogeny. In this project we examined the importance of D1 and D2 receptors for the induction and expression of cocaine-induced behavioral sensitization during the preweanling period. In the behavioral experiments, rats were injected with reversible D1 and/or D2 antagonists (SCH23390 and/or raclopride) or an irreversible receptor antagonist (EEDQ) either before cocaine administration on the pretreatment day (induction) or before cocaine challenge on the test day (expression). In the EEDQ experiments, receptor specificity was assessed by using selective dopamine antagonists to protect D1 and/or D2 receptors from inactivation. Receptor binding assays showed that EEDQ caused substantial reductions in dorsal striatal D1 and D2 binding sites, while SCH23390 and raclopride fully protected D1 and D2 receptors from EEDQ-induced alkylation. Behavioral results showed that neither D1 nor D2 receptor stimulation was necessary for the induction of cocaine sensitization in preweanling rats. EEDQ disrupted the sensitization process, suggesting that another receptor type sensitive to EEDQ alkylation was necessary for the induction process. Expression of the sensitized response was prevented by an acute injection of a D1 receptor antagonist. The pattern of DA antagonist-induced effects described for preweanling rats is, with few exceptions, similar to what is observed when the same drugs are administered to adult rats. Thus, it appears that maturational changes in D1 and D2 receptor systems are not responsible for ontogenetic differences in the behavioral manifestation of cocaine sensitization.


Subject(s)
Behavior, Animal/drug effects , Central Nervous System Sensitization/drug effects , Cocaine/pharmacology , Dopamine Antagonists/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Neostriatum/drug effects , Receptors, Dopamine D1/drug effects , Receptors, Dopamine D2/drug effects , Age Factors , Animals , Benzazepines/pharmacology , Dopamine D2 Receptor Antagonists/pharmacology , Female , Quinolines/administration & dosage , Quinolines/pharmacology , Raclopride/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/antagonists & inhibitors
3.
Cell Stem Cell ; 19(6): 709-724, 2016 12 01.
Article in English | MEDLINE | ID: mdl-27618216

ABSTRACT

Mitochondrial movements are tightly controlled to maintain energy homeostasis and prevent oxidative stress. Miro is an outer mitochondrial membrane protein that anchors mitochondria to microtubule motors and is removed to stop mitochondrial motility as an early step in the clearance of dysfunctional mitochondria. Here, using human induced pluripotent stem cell (iPSC)-derived neurons and other complementary models, we build on a previous connection of Parkinson's disease (PD)-linked PINK1 and Parkin to Miro by showing that a third PD-related protein, LRRK2, promotes Miro removal by forming a complex with Miro. Pathogenic LRRK2G2019S disrupts this function, delaying the arrest of damaged mitochondria and consequently slowing the initiation of mitophagy. Remarkably, partial reduction of Miro levels in LRRK2G2019S human neuron and Drosophila PD models rescues neurodegeneration. Miro degradation and mitochondrial motility are also impaired in sporadic PD patients. We reveal that prolonged retention of Miro, and the downstream consequences that ensue, may constitute a central component of PD pathogenesis.


Subject(s)
Mitochondrial Proteins/metabolism , Mitophagy , Parkinson Disease/metabolism , Parkinson Disease/pathology , Proteolysis , rho GTP-Binding Proteins/metabolism , Animals , Axons/metabolism , Cell Line , Dopaminergic Neurons/metabolism , Drosophila melanogaster/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/metabolism , Mitochondria/metabolism , Motor Activity , Mutation/genetics , Nerve Degeneration/complications , Nerve Degeneration/metabolism , Nerve Degeneration/pathology , Neuroprotection , Parkinson Disease/complications , Protein Binding , Protein Kinases/metabolism , RNA Interference , Signal Transduction , Stress, Physiological , Ubiquitin-Protein Ligases/metabolism
4.
Psychopharmacology (Berl) ; 233(5): 893-903, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26650612

ABSTRACT

RATIONALE: There is suggestive evidence that the neural mechanisms mediating one-trial and multi-trial behavioral sensitization differ, especially when the effects of various classes of dopamine (DA) agonists are examined. OBJECTIVE: The purpose of the present study was to determine the role of the D2 receptor for the induction of one-trial and multi-trial methamphetamine sensitization in preweanling rats. METHODS: In a series of experiments, rats were injected with saline or raclopride (a selective D2 receptor antagonist), either alone or in combination with SCH23390 (a selective D1 receptor antagonist), 15 min prior to treatment with the indirect DA agonist methamphetamine. Acute control groups were given two injections of saline. This pretreatment regimen occurred on either postnatal days (PD) 13-16 (multi-trial) or PD 16 (one-trial). On PD 17, rats were challenged with methamphetamine and locomotor sensitization was determined. RESULTS: Blockade of D2 or D1/D2 receptors reduced or prevented, respectively, the induction of multi-trial methamphetamine sensitization in young rats, while the same manipulations had minimal effects on one-trial behavioral sensitization. CONCLUSIONS: DA antagonist treatment differentially affected the methamphetamine-induced sensitized responding of preweanling rats depending on whether a one-trial or multi-trial procedure was used. The basis for this effect is uncertain, but there was some evidence that repeated DA antagonist treatment caused nonspecific changes that produced a weakened sensitized response. Importantly, DA antagonist treatment did not prevent the one-trial behavioral sensitization of preweanling rats. The latter result brings into question whether DA receptor stimulation is necessary for the induction of psychostimulant-induced behavioral sensitization during early ontogeny.


Subject(s)
Behavior, Animal/drug effects , Central Nervous System Stimulants/pharmacology , Dopamine Antagonists/pharmacology , Dopamine D2 Receptor Antagonists/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Methamphetamine/pharmacology , Receptors, Dopamine D1/antagonists & inhibitors , Receptors, Dopamine D2/drug effects , Animals , Benzazepines/pharmacology , Female , Motor Activity/drug effects , Raclopride/pharmacology , Rats , Rats, Sprague-Dawley
5.
Psychopharmacology (Berl) ; 231(21): 4167-77, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24740494

ABSTRACT

RATIONALE: The neural mechanisms mediating the ontogeny of behavioral sensitization are poorly understood. OBJECTIVE: The purpose of the present study was to determine the role of the D1 receptor for the induction of dopamine agonist-induced behavioral sensitization during the preweanling period. METHODS: In the first experiment, the early ontogeny of R-propylnorapomorphine (NPA)-induced behavioral sensitization was examined by pretreating male and female rats with saline or NPA (0.5, 1, or 2 mg/kg, intraperitoneally (IP)) before placement in activity chambers on postnatal day (PD) 12, 16, 20, or 24. One day later, rats were tested with lower doses of NPA and the occurrence of locomotor sensitization was determined. In subsequent experiments, rats were injected with saline or the D1 receptor antagonist SCH23390 (0.1, 0.5, 1, or 5 mg/kg, IP) 0, 15, 30, or 60 min before cocaine, methamphetamine (METH), or NPA pretreatment. The next day, rats were tested with the same dopamine agonist again and sensitized responding was assessed. RESULTS: NPA produced one-trial behavioral sensitization at all ages tested. In preweanling rats, SCH23390, regardless of dose, was ineffective at preventing the induction of cocaine-, METH-, or NPA-induced one-trial behavioral sensitization. CONCLUSIONS: The present results are in partial contrast to adult rodent studies, in which SCH23390 blocks the induction of METH- and apomorphine-induced behavioral sensitization, but not cocaine sensitization. When these findings are considered together, it appears that D1 receptor stimulation is not necessary for the induction of behavioral sensitization during the preweanling period, although D1 receptors may play a more important role in adulthood.


Subject(s)
Behavior, Animal/drug effects , Dopamine Agonists/pharmacology , Learning/drug effects , Motor Activity/drug effects , Receptors, Dopamine D1/metabolism , Aging/drug effects , Animals , Apomorphine/analogs & derivatives , Apomorphine/pharmacology , Benzazepines/pharmacology , Central Nervous System Stimulants/pharmacology , Cocaine/pharmacology , Female , Male , Methamphetamine/pharmacology , Rats , Rats, Sprague-Dawley
6.
Psychopharmacology (Berl) ; 231(4): 651-62, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24057816

ABSTRACT

RATIONALE: Inactivating dopamine (DA) receptors in the caudate-putamen (CPu) attenuates basal and DA agonist-induced behaviors of adult rats while paradoxically increasing the locomotor activity of preweanling rats. OBJECTIVE: The purpose of this study was to determine (a) whether D1 or D2 receptor inactivation is responsible for the elevated locomotion shown by preweanling rats and (b) whether DA receptor inactivation produces a general state in which any locomotor-activating drug will cause a potentiated behavioral response. METHODS: Dimethyl sulfoxide (DMSO) or N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was bilaterally infused into the CPu on postnatal day (PD) 17. In experiment 1, DA receptors were selectively protected from EEDQ-induced alkylation by pretreating rats with D1 and/or D2 antagonists. On PD 18, rats received bilateral microinjections of the DA agonist R(-)-propylnorapomorphine into the dorsal CPu, and locomotor activity was measured for 40 min. In subsequent experiments, the locomotion of DMSO- and EEDQ-pretreated rats was assessed after intraCPu infusions of the selective DA agonists SKF82958 and quinpirole, the partial agonist terguride, or after systemic administration of nonDAergic compounds. RESULTS: Experiment 1 showed that EEDQ's ability to enhance the locomotor activity of preweanling rats was primarily due to the inactivation of D2 receptors. Consistent with this finding, only drugs that directly or indirectly stimulated D2 receptors produced a potentiated locomotor response in EEDQ-treated rats. CONCLUSIONS: These results show that DA receptor inactivation causes dramatically different behavioral effects in preweanling and adult rats, thus providing additional evidence that the D2 receptor system is not functionally mature by the end of the preweanling period.


Subject(s)
Caudate Nucleus/metabolism , Putamen/metabolism , Receptors, Dopamine D2/metabolism , Aging , Alkylating Agents/pharmacology , Animals , Apomorphine/analogs & derivatives , Apomorphine/pharmacology , Benzazepines/pharmacology , Caudate Nucleus/drug effects , Caudate Nucleus/growth & development , Dimethyl Sulfoxide/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Dopamine D2 Receptor Antagonists , Female , Lisuride/analogs & derivatives , Lisuride/pharmacology , Male , Motor Activity/drug effects , Motor Activity/physiology , Putamen/drug effects , Putamen/growth & development , Quinolines/pharmacology , Quinpirole/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/agonists , Receptors, Dopamine D1/antagonists & inhibitors , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/agonists , Weaning
7.
Psychopharmacology (Berl) ; 231(8): 1637-47, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24287603

ABSTRACT

RATIONALE: Dopamine (DA) receptor inactivation produces opposing behavioral effects across ontogeny. For example, inactivating DA receptors in the dorsal striatum attenuates DA agonist-induced behaviors of adult rats, while potentiating the locomotor activity of preweanling rats. OBJECTIVE: The purpose of this study was to determine if DA receptor inactivation potentiates the DA agonist-induced locomotor activity of adolescent rats and whether alterations in D2(High) receptors are responsible for this effect. METHODS: In the behavioral experiment, the irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or its vehicle (100 % dimethyl sulfoxide, DMSO) was bilaterally infused into the dorsal striatum on postnatal day (PD) 39. On PD 40, adolescent rats were given intrastriatal infusions of the DA agonist R(-)-propylnorapomorphine (NPA) or vehicle and locomotor activity was measured for 40 min. In the receptor binding experiment, rats received IP injections of EEDQ or DMSO (1:1 (v/v) in distilled water) on PD 17, PD 39, or PD 84. One day later, striatal samples were taken and subsequently assayed for D2-specific binding and D2(High) receptors using [(3)H]-domperidone. RESULTS: Unlike what is observed during the preweanling period, EEDQ attenuated the NPA-induced locomotor activity of adolescent rats. EEDQ reduced D2 receptor levels in the dorsal striatum of all age groups while increasing the proportion of D2(High) receptors. Regardless of pretreatment condition (i.e., DMSO or EEDQ), preweanling rats had a greater percentage of D2(High) receptors than adolescent or adult rats. CONCLUSIONS: DA receptor inactivation affects the behaviors of preweanling and older rats differently. The DA supersensitivity exhibited by EEDQ-treated preweanling rats may result from an excess of D2(High) receptors.


Subject(s)
Corpus Striatum/drug effects , Corpus Striatum/growth & development , Motor Activity/drug effects , Motor Activity/physiology , Receptors, Dopamine D2/metabolism , Animals , Apomorphine/analogs & derivatives , Apomorphine/pharmacology , Autoradiography , Corpus Striatum/physiology , Domperidone/pharmacology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Female , Male , Quinolines/pharmacology , Rats , Receptors, Dopamine D2/agonists , Sex Characteristics , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...